个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Reduced Ceftazidime-Avibactam Susceptibility in KPC-Producing Klebsiella pneumoniae From Patients Without Ceftazidime-Avibactam Use History – A Multicenter Study in China(Open Access)

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Cui, X[a] * ; Shan, B[b] * ; Zhang, X[a] ; Qu, F[c,d] ; Jia, W[e] ; Huang, B[f] ; Yu, H[g] ; Tang, Y.-W[h,i,j] ; Chen, L[k,l] ; Du, H[a] ;
机构： [a]Department of Clinical Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China [b]Department of Clinical Laboratory, The First Affiliated Hospital of Kunming Medical University, Kunming, China [c]Center for Clinical Laboratory, 302 Hospital of PLA, Beijing, China [d]Aviation General Hospital, China Medical University, Beijing, China [e]Medical Laboratory Center, General Hospital of Ningxia Medical University, Yinchuan, China [f]Department of Laboratory Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China [g]Sichuan Academy of Medical Sciences Sichuan Provincial People’s Hospital, Chengdu, China [h]Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States [i]Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, Cornell University, New York, NY, United States [j]Cepheid, Shanghai, China [k]Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, United States [l]Hackensack Meridian School of Medicine at, Seton Hall University, Nutley, NJ, United States
出处：
DOI： 10.3389/fmicb.2020.01365
ISSN：

关键词： antimicrobial resistance antimicrobial susceptibility ceftazidime-avibactam Klebsiella pneumoniae KPC

摘要：
KPC-producing Klebsiella pneumoniae (KPC-KP) is the most widely spread carbapenem-resistant Enterobacteriaceae (CRE) in China. Avibactam is a novel non-β-lactam β-lactamase inhibitor which is highly active against KPC. Recently, ceftazidime-avibactam (CAZ-AVI) was approved for clinical treatment in China. Here we conducted a retrospective study to examine the antimicrobial susceptibility of CAZ-AVI prior to its usage in China, and evaluated the potential to develop resistance in KPC-KP. CAZ-AVI MICs were tested in 347 KPC-KP isolates collected from patients with no prior treatment with this combination from six medical centers in China. Almost all isolates (n = 346; 99.7%) were CAZ-AVI-susceptible, with only 12 (3.5%) which showed reduced susceptibility (MIC ≥ 4/4 μg/ml) or resistance. The 12 isolates belong to ST11 and half of them carry virulence genes. In comparison to susceptible isolates, these isolates demonstrated higher blaKPC–2 copy numbers and expressions, and demonstrated higher frequency of developing CAZ-AVI resistance. © Copyright © 2020 Cui, Shan, Zhang, Qu, Jia, Huang, Yu, Tang, Chen and Du.

基金：
Funding. This study was supported by the National Natural Science Foundation of China (81572032), the Six Talent Peaks Project in Jiangsu Province (2016-WSN-112), the Key Research and Development Project of Jiangsu Provincial Science and Technology Department (BE2017654), Gusu Key Health Talent of Suzhou, the Jiangsu Youth Medical Talents Program (QN-867), and the Science and Technology Program of Suzhou (SZS201715 and SLT201934).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2021]版：
大类 | 2 区 生物
小类 | 2 区 微生物学
最新[2023]版：
大类 | 2 区 生物学
小类 | 3 区 微生物学
JCR分区：
出版当年[2020]版：
Q1 MICROBIOLOGY
最新[2023]版：
Q2 MICROBIOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者：
第一作者机构： [a]Department of Clinical Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Cui X,Shan B,Zhang X,et al.Reduced Ceftazidime-Avibactam Susceptibility in KPC-Producing Klebsiella pneumoniae From Patients Without Ceftazidime-Avibactam Use History – A Multicenter Study in China(Open Access)[J].FRONTIERS IN MICROBIOLOGY.2020,11:doi:10.3389/fmicb.2020.01365.
APA：
Cui, X,Shan, B,Zhang, X,Qu, F,Jia, W...&Du, H.(2020).Reduced Ceftazidime-Avibactam Susceptibility in KPC-Producing Klebsiella pneumoniae From Patients Without Ceftazidime-Avibactam Use History – A Multicenter Study in China(Open Access).FRONTIERS IN MICROBIOLOGY,11,
MLA：
Cui, X,et al."Reduced Ceftazidime-Avibactam Susceptibility in KPC-Producing Klebsiella pneumoniae From Patients Without Ceftazidime-Avibactam Use History – A Multicenter Study in China(Open Access)".FRONTIERS IN MICROBIOLOGY 11.(2020)

相关文献

[1]Clinical Outcomes and Risk Factors for Death in Critically Ill Patients with Carbapenem-Resistant Klebsiella pneumoniae Treated with Ceftazidime-Avibactam: A Retrospective Study [2]Efficacy of ceftazidime-avibactam with or without polymyxin for carbapenem-resistant Klebsiella pneumoniae infections after initial treatment with polymyxin [3]2015-2021年chinet临床分离铜绿假单胞菌耐药性变迁 [4]NDM-1-Positive K. pneumoniae at a Teaching Hospital in Southwestern China: Clinical Characteristics, Antimicrobial Resistance, Molecular Characterization, Biofilm Assay, and Virulence. [5]2005—2014年CHINET脑脊液分离菌分布和耐药性监测 [6]Resistance reported from China antimicrobial surveillance network (CHINET) in 2018 [7]2012年中国CHINET克雷伯菌属细菌耐药性监测 [8]Antimicrobial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated from community-acquired respiratory tract infections in China: Results from the CARTIPS Antimicrobial Surveillance Program [9]2011年昆明医科大学第一附属医院肺炎克雷伯菌耐药性监测 [10]2013年昆明医科大学第一附属医院肺炎克雷伯菌耐药性监测及分析

资源点击量：56920 今日访问量：0 总访问量：1772 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 昆明医科大学第一附属医院 技术支持：重庆聚合科技有限公司 地址：云南省昆明市西昌路295号(650032)